Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings

The multiple clinical benefits of hydroxycarbamide in sickle cell disease are supported by a large body of evidence. The maximum tolerated dose (MTD) is the regimen recommended by guidelines from a panel of National Heart, Lung, and Blood Institute (NHLBI) experts, but other dosage regimens have bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Inusa, Baba Psalm Duniya, Atoyebi, Wale, Hassan, Abdul Aziz, Idhate, Tushar, Dogara, Livingstone, Ijei, Ifeoma, Qin, Yewen, Anie, Kofi, Lawson, Juliana Olufunke, Hsu, Lewis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124375/
https://www.ncbi.nlm.nih.gov/pubmed/30228870
http://dx.doi.org/10.12688/f1000research.14589.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124375/
https://www.ncbi.nlm.nih.gov/pubmed/30228870
http://dx.doi.org/10.12688/f1000research.14589.1

Ejemplares similares